Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631510 · ClinicalTrials.gov registry record · Early Phase 1
Gabapentin for Sleep in Critically Ill Patients
A Early Phase 1 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
NCT04631510 is a Early Phase 1 study that has completed, run by Tufts Medical Center. The registered enrollment target is 80 participants.
The verdict
NCT04631510, a Early Phase 1 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
Sleep disruption in the intensive care unit (ICU) is a common comorbidity associated with patient morbidity and distress. There are no recommended pharmacologic interventions for sleep promotion, and many pharmacologic solutions may actually increase the risk of adverse outcomes rather than impart benefits. Gabapentin, an anticonvulsant with applications in neuropathic pain, has been investigated for sleep promotion in various populations of outpatients. Here investigators propose a pilot study of gabapentin as a therapy for sleep disruption in the ICU. Outcomes measured will be sleep quality as measured by RCSQ (Richards-Campbell Sleep Questionnaire), wrist actigraphy, EEG, and BIS monitoring. The goal is to enroll 80 critically ill patients, 40 intubated and 40 non-intubated patients. The study will take place over 2 nights, with baseline sleep measurements occurring on the first night and gabapentin administration with repeat sleep measurements on the second night.
Interventions
- DRUG Gabapentin 300 mg PO at 8 PM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-05-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04631510
The ClinicalTrials.gov registry entry for NCT04631510 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin 300 mg PO at 8 PM is the first listed.
NCT04631510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04631510 about?
NCT04631510 is a clinical study titled "Gabapentin for Sleep in Critically Ill Patients". Sleep disruption in the intensive care unit (ICU) is a common comorbidity associated with patient morbidity and distress. There are no recommended pharmacologic interventions for sleep promotion, and many pharmacologic solutions may actually increase the risk of adverse outcomes rather than impart b...
What is the current status of trial NCT04631510?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2020-12-01. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT04631510?
The interventions under investigation include: Gabapentin 300 mg PO at 8 PM (DRUG).
Who is sponsoring clinical trial NCT04631510?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.